Immunic Therapeutics has closed a private placement that could provide up to $400 million to support the company’s Phase 3 clinical program of vidofludimus calcium in multiple sclerosis (MS) and help fund its transition into a commercial-stage company as it prepares for potential regulatory approval of the…
vidofludimus calcium
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium can target key mechanisms underlying disease progression in multiple sclerosis (MS), including acute and chronic inflammation, as well as Epstein-Barr virus (EBV) reactivation, according to new trial data. The Phase 2 CALLIPER trial (NCT05054140)Â investigated vidofludimus calcium against a…
Recommended Posts
- New method confirms positive clinical trial results for MS drug Tecfidera
- AAN 2026: AI-powered MS blood test sees growing use in real-world care
- AAN 2026: Ocrevus preserves walking, hand function in early RRMS
- My husband’s MS diagnosis changed everything — and nothing
- Enrollment complete in Phase 3 trial of at-home Briumvi injection for MS